Sanofi SNY and partner Teva Pharmaceuticals TEVA announced positive data from the phase IIb RELIEVE UCCD study on their ...

Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting ...

As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...

The TL1A drug would serve as a companion to Sanofi and partner Regeneron's multibillion-dollar blockbuster Dupixent ...

Sanofi & Teva Pharma’s RELIEVE UCCD phase 2b study of duvakitug in ulcerative colitis and Crohn’s disease meets primary endpoints: Paris Thursday, December 19, 2024, 11:00 Hrs ...

Sanofi (SNY) and Teva Pharmaceuticals (TEVA) announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi (SNY) announce that the Phase 2b RELIEVE UCCD study ...

as the partners released what analysts called “best-in-class” results from the phase IIb Relieve UCCD study and prepare for a ...

PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb ...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary ...

13.0% at low dose. RELIEVE UCCD investigated duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for moderate-to-severe inflammatory bowel disease (IBD).